My concern (alluded to yesterday) was that Baker Bros/Acadia might be taking advantage of current circumstances (NEU share price being battered by the Coronavirus market rout and the Acadia decision to pause the Phase 3 trofinetide in Rett trial) to grab a blocking stake in the company and perhaps a Board presence.
Firstly, from an ethical perspective, it wouldn’t sit well with me if Acadia made such a move directly after pausing the trofinetide trial but none of its own trials of pimavanserin.
In addition, I would have concerns that, for an investment of just US$8.5m, Baker Bros/Acadia could in future (improved) times, control Neuren’s deal options.
In short, I’m relieved that there is no evidence that our trofinetide partner is engaging in what I would view as predatory behaviour.
Ann: International institution acquires 14% of Neuren, page-21
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.62 |
Change
-0.240(1.15%) |
Mkt cap ! $2.635B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $20.62 | $20.26 | $4.698M | 229.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 221 | $20.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.62 | 1553 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |